{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T19:46:01Z","timestamp":1775504761847,"version":"3.50.1"},"reference-count":92,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T00:00:00Z","timestamp":1650240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["21ck0106509s0203"],"award-info":[{"award-number":["21ck0106509s0203"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["21ck0106670s0701"],"award-info":[{"award-number":["21ck0106670s0701"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Labor, Health, and Welfare of Japan","award":["21K08412"],"award-info":[{"award-number":["21K08412"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>More than half of patients with malignant lymphoma are 65\u00a0years old or older. The outcome for older patients is poorer than that for younger patients. A poor prognosis is associated with heterogeneity and consists of physical function, performance status, poor nutritional status and various comorbidities. Therefore, attention should be given to serious treatment-related toxicities. Diffuse large B-cell lymphoma is the most frequently diagnosed type of malignant lymphoma. Most patients with diffuse large B-cell lymphoma can be potentially cured with the current standard chemotherapeutic regimen of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. However, a reduced-dose regimen of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or alternative treatment options might be suitable for older patients who are frail or unfit and have cardiac comorbidities. A comprehensive geriatric assessment is a potential tool for determining an appropriate therapeutic approach for each older patient. Follicular lymphoma is the second most common type of non-Hodgkin lymphoma, and the disease course is usually characterized by an indolent clinical course. Advanced follicular lymphoma with a high tumor burden has historically been treated with chemoimmunotherapy, but the treatment goal for older patients is relief of symptoms. Incorporating novel targeted agents such as brentuximab vedotin into therapies for older Hodgkin lymphoma patients might be a promising alternative to the anthracycline-containing regimen.<\/jats:p>","DOI":"10.1093\/jjco\/hyac056","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T11:18:22Z","timestamp":1649935102000},"page":"690-699","source":"Crossref","is-referenced-by-count":5,"title":["Management of elderly patients with malignant lymphoma"],"prefix":"10.1093","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6547-3181","authenticated-orcid":false,"given":"Kana","family":"Miyazaki","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Mie University Graduate School of Medicine , Tsu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,4,18]]},"reference":[{"key":"2022093018253797200_ref1","author":"Surveillance, Epidemiology, and End Results (SEER) Program","year":"2020"},{"key":"2022093018253797200_ref2","author":"Cancer Statistics in Japan"},{"key":"2022093018253797200_ref3","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1440-1827.2007.02207.x","article-title":"Distribution of malignant lymphoma in Japan: analysis of 2260 cases, 2001-2006","volume":"58","author":"Aoki","year":"2008","journal-title":"Pathol Int"},{"key":"2022093018253797200_ref4","doi-asserted-by":"crossref","first-page":"5843","DOI":"10.1002\/cam4.1805","article-title":"Epidemiology and secular trends of malignant lymphoma in Japan: analysis of 9426 cases according to the World Health Organization classification","volume":"7","author":"Muto","year":"2018","journal-title":"Cancer Med"},{"key":"2022093018253797200_ref5","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"2022093018253797200_ref6","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"2022093018253797200_ref7","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"key":"2022093018253797200_ref8","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N Engl J Med"},{"key":"2022093018253797200_ref9","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.3324\/haematol.2011.050617","article-title":"The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age","volume":"96","author":"Mareschal","year":"2011","journal-title":"Haematol-Hematol J"},{"key":"2022093018253797200_ref10","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"key":"2022093018253797200_ref11","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"key":"2022093018253797200_ref12","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.ccell.2021.10.006","article-title":"Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL","volume":"39","author":"Wilson","year":"2021","journal-title":"Cancer Cell"},{"key":"2022093018253797200_ref13","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"2022093018253797200_ref14","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"2022093018253797200_ref15","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood-2003-06-2095","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"key":"2022093018253797200_ref16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"key":"2022093018253797200_ref17","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(13)60313-X","article-title":"Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles","volume":"381","author":"Cunningham","year":"2013","journal-title":"The Lancet"},{"key":"2022093018253797200_ref18","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(13)70122-0","article-title":"Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial","volume":"14","author":"Delarue","year":"2013","journal-title":"Lancet Oncol"},{"key":"2022093018253797200_ref19","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1093\/annonc\/mdx128","article-title":"Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial","volume":"28","author":"Kuhnl","year":"2017","journal-title":"Ann Oncol"},{"key":"2022093018253797200_ref20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJM199807023390104","article-title":"Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma","volume":"339","author":"Miller","year":"1998","journal-title":"N Engl J Med"},{"key":"2022093018253797200_ref21","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1200\/JCO.2007.13.6929","article-title":"Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014","volume":"26","author":"Persky","year":"2008","journal-title":"J Clin Oncol"},{"key":"2022093018253797200_ref22","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3109\/10428194.2014.930853","article-title":"Limited stage diffuse large B-cell lymphoma: comparative effectiveness of treatment strategies in a large cohort of elderly patients","volume":"56","author":"Odejide","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"2022093018253797200_ref23","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1182\/blood-2017-07-793984","article-title":"R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma","volume":"131","author":"Lamy","year":"2018","journal-title":"Blood"},{"key":"2022093018253797200_ref24","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1002\/cncr.24490","article-title":"A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy","volume":"115","author":"Tucci","year":"2009","journal-title":"Cancer"},{"key":"2022093018253797200_ref25","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3109\/10428194.2014.953142","article-title":"Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL)","volume":"56","author":"Tucci","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"2022093018253797200_ref26","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1200\/JCO.20.02465","article-title":"Simplified geriatric assessment in older patients with diffuse large B-cell lymphoma: the prospective elderly project of the Fondazione Italiana Linfomi","volume":"39","author":"Merli","year":"2021","journal-title":"J Clin Oncol"},{"key":"2022093018253797200_ref27","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjh.13619","article-title":"Results of a large retrospective analysis of the effect of intended dose intensity of R-CHOP on outcome in a cohort of consecutive, unselected elderly patients with de novo diffuse large B cell lymphoma","volume":"173","author":"Eyre","year":"2016","journal-title":"Br J Haematol"},{"key":"2022093018253797200_ref28","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jgo.2015.01.003","article-title":"Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma","volume":"6","author":"Carson","year":"2015","journal-title":"J Geriatr Oncol"},{"key":"2022093018253797200_ref29","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","article-title":"Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial","volume":"12","author":"Peyrade","year":"2011","journal-title":"Lancet Oncol"},{"key":"2022093018253797200_ref30","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/ejh.12459","article-title":"Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: consortium for improving survival of lymphoma study (CISL)","volume":"94","author":"Jung","year":"2015","journal-title":"Eur J Haematol"},{"key":"2022093018253797200_ref31","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1093\/annonc\/mdq671","article-title":"Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas","volume":"22","author":"Weidmann","year":"2011","journal-title":"Ann Oncol"},{"key":"2022093018253797200_ref32","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.3324\/haematol.2017.186569","article-title":"Rituximab plus bendamustine as front-line treatment in frail elderly (&gt;70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi","volume":"103","author":"Storti","year":"2018","journal-title":"Haematologica"},{"key":"2022093018253797200_ref33","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/bjh.14232","article-title":"A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma","volume":"175","author":"Park","year":"2016","journal-title":"Br J Haematol"},{"key":"2022093018253797200_ref34","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1007\/s00277-019-03819-3","article-title":"Is bendamustine-rituximab a reasonable treatment in selected older patients with diffuse large B cell lymphoma? Results from a multicentre, retrospective study","volume":"98","author":"Zeremski","year":"2019","journal-title":"Ann Hematol"},{"key":"2022093018253797200_ref35","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1200\/JCO.2005.12.121","article-title":"Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia","volume":"23","author":"Lipshultz","year":"2005","journal-title":"J Clin Oncol"},{"key":"2022093018253797200_ref36","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3109\/10428194.2011.621565","article-title":"Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly \"fit\" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi","volume":"53","author":"Merli","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"2022093018253797200_ref37","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.2013.49.7586","article-title":"De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial","volume":"32","author":"Fields","year":"2014","journal-title":"J Clin Oncol"},{"key":"2022093018253797200_ref38","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/annonc\/mdp544","article-title":"Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial","volume":"21","author":"Luminari","year":"2010","journal-title":"Ann Oncol"},{"key":"2022093018253797200_ref39","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1365-2141.2011.08786.x","article-title":"Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high 'life threat' impact cardiopathy","volume":"154","author":"Corazzelli","year":"2011","journal-title":"Br J Haematol"},{"key":"2022093018253797200_ref40","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.3109\/10428194.2011.572321","article-title":"Non-pegylated liposomal doxorubicin (Myocet(R)) in patients with poor-risk aggressive B-cell non-Hodgkin lymphoma","volume":"52","author":"Dell'Olio","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"2022093018253797200_ref41","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.clml.2014.09.001","article-title":"Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial","volume":"15","author":"Oki","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2022093018253797200_ref42","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3816\/CLML.2010.n.004","article-title":"Brief-duration rituximab\/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium","volume":"10","author":"Hainsworth","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2022093018253797200_ref43","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1182\/bloodadvances.2020002982","article-title":"Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines","volume":"5","author":"Moccia","year":"2021","journal-title":"Blood Adv"},{"key":"2022093018253797200_ref44","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/cncr.25582","article-title":"Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma","volume":"117","author":"Musolino","year":"2011","journal-title":"Cancer"},{"key":"2022093018253797200_ref45","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s00277-016-2768-x","article-title":"R-CVP regimen is active in frail elderly patients aged 80 or over with diffuse large B cell lymphoma","volume":"95","author":"Laribi","year":"2016","journal-title":"Ann Hematol"},{"key":"2022093018253797200_ref46","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update","volume":"33","author":"Smith","year":"2015","journal-title":"J Clin Oncol"},{"key":"2022093018253797200_ref47","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","article-title":"2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours","volume":"47","author":"Aapro","year":"2011","journal-title":"Eur J Cancer"},{"key":"2022093018253797200_ref48","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1634\/theoncologist.12-12-1416","article-title":"Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim","volume":"12","author":"Balducci","year":"2007","journal-title":"Oncologist"},{"key":"2022093018253797200_ref49","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1007\/s00520-017-3747-z","article-title":"Incidence and risk factors of febrile neutropenia in patients with non-Hodgkin B-cell lymphoma receiving R-CHOP in a single center in Japan","volume":"25","author":"Yokoyama","year":"2017","journal-title":"Support Care Cancer"},{"key":"2022093018253797200_ref50","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.jiac.2021.03.004","article-title":"Difference of preventing effects of G-CSF according to age in patients with malignant lymphoma: a nation-wide analysis in Japan","volume":"27","author":"Matsuda","year":"2021","journal-title":"J Infect Chemother"},{"key":"2022093018253797200_ref51","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.6004\/jnccn.2016.0121","article-title":"Risk factors for early death after rituximab-based immunochemotherapy in older patients with diffuse large B-cell lymphoma","volume":"14","author":"Olszewski","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"2022093018253797200_ref52","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jgo.2020.06.018","article-title":"Duration of short-acting granulocyte colony-stimulating factor for primary prophylaxis and risk of neutropenia-related hospitalization in older patients with cancer","volume":"11","author":"Li","year":"2020","journal-title":"J Geriatr Oncol"},{"key":"2022093018253797200_ref53","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","article-title":"Follicular lymphoma in the United States: first report of the national LymphoCare study","volume":"27","author":"Friedberg","year":"2009","journal-title":"J Clin Oncol"},{"key":"2022093018253797200_ref54","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JCO.18.00400","article-title":"Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts","volume":"37","author":"Sarkozy","year":"2019","journal-title":"J Clin Oncol"},{"key":"2022093018253797200_ref55","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1182\/bloodadvances.2020002724","article-title":"Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials","volume":"5","author":"Casulo","year":"2021","journal-title":"Blood Adv"},{"key":"2022093018253797200_ref56","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/bjh.15805","article-title":"Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population","volume":"185","author":"Magnano","year":"2019","journal-title":"Br J Haematol"},{"key":"2022093018253797200_ref57","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"The Lancet"},{"key":"2022093018253797200_ref58","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"Lancet Oncol"},{"key":"2022093018253797200_ref59","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2012.45.0866","article-title":"R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi","volume":"31","author":"Federico","year":"2013","journal-title":"J Clin Oncol"},{"key":"2022093018253797200_ref60","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"The Lancet"},{"key":"2022093018253797200_ref61","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"The Lancet"},{"key":"2022093018253797200_ref62","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1200\/JCO.2017.76.8960","article-title":"Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety","volume":"36","author":"Hiddemann","year":"2018","journal-title":"J Clin Oncol"},{"key":"2022093018253797200_ref63","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1046\/j.1365-2141.2002.03815.x","article-title":"Hodgkin's disease in the elderly: a population-based study","volume":"119","author":"Stark","year":"2002","journal-title":"Br J Haematol"},{"key":"2022093018253797200_ref64","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/ejh.13090","article-title":"Greater attention should be paid to developing therapies for elderly patients with Hodgkin lymphoma-A population-based study from Sweden","volume":"101","author":"Bjorkholm","year":"2018","journal-title":"Eur J Haematol"},{"key":"2022093018253797200_ref65","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1200\/JCO.2005.11.080","article-title":"Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group","volume":"23","author":"Engert","year":"2005","journal-title":"J Clin Oncol"},{"key":"2022093018253797200_ref66","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1182\/bloodadvances.2021004645","article-title":"Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma","volume":"5","author":"Orellana-Noia","year":"2021","journal-title":"Blood Adv"},{"key":"2022093018253797200_ref67","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"key":"2022093018253797200_ref68","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2010.29.8018","article-title":"Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial","volume":"28","author":"Eich","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022093018253797200_ref69","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1200\/JCO.2012.45.4181","article-title":"ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials","volume":"31","author":"Boll","year":"2013","journal-title":"J Clin Oncol"},{"key":"2022093018253797200_ref70","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.2016.70.9410","article-title":"Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 trials","volume":"35","author":"Sasse","year":"2017","journal-title":"J Clin Oncol"},{"key":"2022093018253797200_ref71","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1200\/JCO.2012.47.9774","article-title":"Treatment-related mortality in patients with advanced-stage hodgkin lymphoma: an analysis of the german hodgkin study group","volume":"31","author":"Wongso","year":"2013","journal-title":"J Clin Oncol"},{"key":"2022093018253797200_ref72","first-page":"438","article-title":"Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis","volume":"88","author":"Landgren","year":"2003","journal-title":"Haematologica"},{"key":"2022093018253797200_ref73","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.12222","article-title":"The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496","volume":"161","author":"Evens","year":"2013","journal-title":"Br J Haematol"},{"key":"2022093018253797200_ref74","doi-asserted-by":"crossref","first-page":"7614","DOI":"10.1200\/JCO.2005.02.7243","article-title":"Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma","volume":"23","author":"Martin","year":"2005","journal-title":"J Clin Oncol"},{"key":"2022093018253797200_ref75","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1182\/blood-2015-11-681064","article-title":"Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials","volume":"127","author":"Boll","year":"2016","journal-title":"Blood"},{"key":"2022093018253797200_ref76","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/bjh.13419","article-title":"Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly","volume":"170","author":"Stamatoullas","year":"2015","journal-title":"Br J Haematol"},{"key":"2022093018253797200_ref77","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1182\/blood-2011-09-378414","article-title":"A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era","volume":"119","author":"Evens","year":"2012","journal-title":"Blood"},{"key":"2022093018253797200_ref78","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab Vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"key":"2022093018253797200_ref79","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2021.278438","article-title":"Older patients (aged &gt;\/=60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study","author":"Evens","year":"2021","journal-title":"Haematologica"},{"key":"2022093018253797200_ref80","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood-2015-06-644336","article-title":"Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older","volume":"126","author":"Forero-Torres","year":"2015","journal-title":"Blood"},{"key":"2022093018253797200_ref81","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/blood-2017-06-787200","article-title":"Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged &gt;\/=60 years with HL","volume":"130","author":"Friedberg","year":"2017","journal-title":"Blood"},{"key":"2022093018253797200_ref82","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2018.79.0139","article-title":"Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma","volume":"36","author":"Evens","year":"2018","journal-title":"J Clin Oncol"},{"key":"2022093018253797200_ref83","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00277-018-3551-y","article-title":"Geriatric screening tools predict survival outcomes in older patients with diffuse large B cell lymphoma","volume":"98","author":"Sakurai","year":"2019","journal-title":"Ann Hematol"},{"key":"2022093018253797200_ref84","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jgo.2013.04.003","article-title":"A retrospective study on 73 elderly patients (&gt;\/=75years) with aggressive B-cell non Hodgkin lymphoma: clinical significance of treatment intensity and comprehensive geriatric assessment","volume":"4","author":"Marchesi","year":"2013","journal-title":"J Geriatr Oncol"},{"key":"2022093018253797200_ref85","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3109\/10428194.2013.788176","article-title":"Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by comprehensive geriatric assessment: results from a study of the Fondazione Italiana Linfomi","volume":"55","author":"Merli","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"2022093018253797200_ref86","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/bjh.16049","article-title":"Comprehensive geriatric assessment is useful in an elderly Australian population with diffuse large B-cell lymphoma receiving rituximab-chemotherapy combinations","volume":"187","author":"Ong","year":"2019","journal-title":"Br J Haematol"},{"key":"2022093018253797200_ref87","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1634\/theoncologist.2011-0417","article-title":"Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma","volume":"17","author":"Spina","year":"2012","journal-title":"Oncologist"},{"key":"2022093018253797200_ref88","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1634\/theoncologist.2011-0355","article-title":"Tailored therapy in an unselected population of 91 elderly patients with DLBCL prospectively evaluated using a simplified CGA","volume":"17","author":"Olivieri","year":"2012","journal-title":"Oncologist"},{"key":"2022093018253797200_ref89","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/ejh.12608","article-title":"Analysis of elderly patients with diffuse large B-cell lymphoma: aggressive therapy is a reasonable approach for 'unfit' patients classified by comprehensive geriatric assessment","volume":"96","author":"Yoshida","year":"2016","journal-title":"Eur J Haematol"},{"key":"2022093018253797200_ref90","doi-asserted-by":"crossref","first-page":"e1202","DOI":"10.1634\/theoncologist.2019-0738","article-title":"Comprehensive geriatric assessment (CGA): a simple tool for guiding the treatment of older adults with diffuse large B-cell lymphoma in China","volume":"25","author":"Bai","year":"2020","journal-title":"Oncologist"},{"key":"2022093018253797200_ref91","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/hon.2524","article-title":"R-THP-COP versus R-CHOP in patients younger than 70 years with untreated diffuse large B cell lymphoma: a randomized, open-label, noninferiority phase 3 trial","volume":"36","author":"Hara","year":"2018","journal-title":"Hematol Oncol"},{"key":"2022093018253797200_ref92","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.leukres.2010.07.024","article-title":"Intermediate dose of nonpegylated liposomal doxorubicin combination (R-CMyOP) as first line chemotherapy for frail elderly patients with aggressive lymphoma","volume":"35","author":"Gimeno","year":"2011","journal-title":"Leuk Res"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/52\/7\/690\/46214774\/hyac056.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/52\/7\/690\/46214774\/hyac056.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T19:47:05Z","timestamp":1664567225000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/52\/7\/690\/6569543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,18]]},"references-count":92,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,4,18]]},"published-print":{"date-parts":[[2022,7,8]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyac056","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7]]},"published":{"date-parts":[[2022,4,18]]}}}